Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term extension study of QX002N in active ankylosing spondylitis
ChiCTR2200065495Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of crusekitug in ankylosing spondylitis (AS), sponsored by Peking Union Medical College Hospital. Primary endpoints: Adverse events and Proportion of subjects achieving ASAS20. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
crusekitug
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on ChiCTR2200065495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065495.